T Ratneswaren, N Chan, J Aeron-Thomas, S Sait, O Adesalu, M Alhawamdeh, M Benger, J Garnham, L Dixon, F Tona, C McNamara, E Taylor, K Lobotesis, E Lim, O Goldberg, N Asmar, O Evbuomwan, S Banerjee, L Holm-Mercer, J Senor, Y Tsitsiou, P Tantrige, A Taha, K Ballal, A Mattar, A Daadipour, K Elfergani, R Barker, R Chakravartty, A G Murchison, B J Kemp, R Simister, I Davagnanam, O Y Wong, D Werring, A Banaras, M Anjari, J C L Rodrigues, C A S Thompson, I R Haines, T A Burnett, R E Y Zaher, V L Reay, M Banerjee, C S L Sew Hee, A P Oo, A Lo, P Rogers, T Hughes, A Marin, S Mukherjee, H Jaber, E Sanders, S Owen, M Bhandari, S Sundayi, A Bhagat, M Elsakka, O H Hashmi, M Lymbouris, Y Gurung-Koney, M Arshad, I Hasan, N Singh, V Patel, M Rahiminejad, T C Booth
BACKGROUND: Apical ground-glass opacification (GGO) identified on CT angiography (CTA) performed for suspected acute stroke was developed in 2020 as a coronavirus-disease-2019 (COVID-19) diagnostic and prognostic biomarker in a retrospective study during the first wave of COVID-19. OBJECTIVE: To prospectively validate whether GGO on CTA performed for suspected acute stroke is a reliable COVID-19 diagnostic and prognostic biomarker and whether it is reliable for COVID-19 vaccinated patients...
March 15, 2024: NeuroImage: Clinical